보고서 요약(국문)

개요
전 세계 말초혈관 혈전 관리 시술 시장은 2022년 YY억 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
혈전을 조기에 발견하고 치료하면 뇌졸중 및 혈관 질환으로 인한 사망률을 크게 줄일 수 있습니다. 혈액 응고는 혈관 손상 시 과다 출혈을 막는 중요한 과정입니다. 혈소판(혈액 세포의 일종)과 혈장(혈액의 액체 부분) 내 단백질이 함께 작용하여 손상 부위에 혈전을 형성함으로써 출혈을 멈춥니다.

또한, 전 세계 말초혈관 혈전 관리 시술 시장은 심혈관 질환의 세계적 발병률 증가, 혈전 관리 기기의 기술 발전, 최첨단 기술의 지속적인 개발 등 다양한 요인에 의해 성장하고 있으며, Abbott Laboratories, Edward Lifesciences Corporation, Medtronic Inc, Teleflex Medical 등의 주요 기업들이 시장을 주도하고 있습니다. 이러한 요인들은 향후 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
시장 동향
혈관 질환 유병률 증가
혈관 질환 유병률 증가는 예측 기간 동안 시장 성장을 촉진하는 주요 요인 중 하나입니다. 말초동맥질환(PAD) 및 심부정맥혈전증(DVT)과 같은 질환의 유병률은 흡연, 비만, 좌식 생활 습관과 같은 생활 방식 요인으로 인해 증가하고 있으며, 이는 혈전 관리 시술에 대한 수요를 증가시키고 있습니다.

예를 들어, 미국 질병통제예방센터(CDC)의 최신 자료에 따르면 심부정맥혈전증(DVT) 또는 폐색전증(PE)의 정확한 발병률은 알려져 있지 않지만, 미국에서만 매년 최대 90만 명이 발병할 수 있다고 추정됩니다.
노년 인구 증가로 인한 발병률 증가
노년층은 운동 능력 저하, 만성 질환(예: 고혈압, 당뇨병, 심장병), 복용 중인 약물 등 연령 관련 요인으로 인해 혈전 발생 위험이 더 높습니다. 예를 들어, 세계보건기구(WHO)는 2020년 10억 명이었던 60세 이상 인구가 2050년에는 21억 명에 이를 것으로 추산합니다.
또한 여러 자료와 연구에 따르면 60세 이상 인구는 심부정맥혈전증(신체 심부정맥에 혈전이 형성되는 질환)의 가장 중요한 독립적인 위험 요인입니다. 따라서 고령 인구의 증가와 이들 사이에서 발생하는 혈전증 부담 증가는 혈전 관리 기기에 대한 수요를 창출하여 분석 기간 동안 시장 성장을 견인할 것으로 예상됩니다.

기기 비용의 높은 부담
말초혈관 혈전 관리 시술 기기는 비용이 많이 들 수 있으며, 이는 일부 환자에게 접근성 장벽이 될 수 있습니다. 이러한 기기의 높은 비용은 시술의 복잡성과 기기에 사용되는 첨단 기술 때문입니다.
예를 들어, 혈관내 동맥류 복구 스텐트 이식편의 비용이 매우 높아 예측 기간 동안 시장 성장을 저해하는 요인이 될 수 있습니다. 동맥류 관련 후속 시술을 위한 입원 비용의 중앙값은 22,023달러(사분위 범위, 13,177달러~47,752달러)였으며, 동맥류와 관련 없는 후속 시술의 입원 비용 중앙값은 19,007달러(사분위 범위, 8,708달러~33,301달러)였습니다.

이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 말초혈관 혈전 관리 시술 시장은 기기 유형, 적응증, 최종 사용자 및 지역별로 세분화됩니다.
기기 유형 세그먼트 중 카테터 세그먼트는 말초혈관 혈전 관리 시술 시장 점유율의 약 41.7%를 차지했습니다.
기기 유형 세그먼트 중 카테터 세그먼트는 41.7%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 카테터는 심부정맥혈전증(DVT) 부위에 혈전 용해제를 주입하는 데 사용됩니다. 이를 통해 혈전을 분해할 수 있으며, 의료진은 작은 도구를 사용하여 혈전을 분해할 수도 있습니다.
카테터 유도 혈전용해술은 비정상적인 혈전을 용해하여 혈관 막힘을 치료하고 혈류를 개선합니다. 혈전은 신체의 특정 부위로 가는 혈액 공급을 차단하여 심각한 손상을 유발할 수 있습니다. 카테터 유도 혈전용해술은 X선 영상과 카테터를 이용하여 특수 약물이나 의료기기를 혈전 부위로 유도하여 막힌 부분을 용해시키는 시술입니다.
예를 들어, 2021년 9월 보스턴 사이언티픽(Boston Scientific Corporation)은 WOLF 혈전제거 플랫폼 개발사인 데보로 메디컬(Devoro Medical, Inc.)을 인수하는 계약을 체결했다고 발표했습니다. 혁신적인 콘솔 없는 WOLF 기술은 손가락 모양의 갈고리를 사용하여 동맥 및 정맥계의 혈전을 신속하게 제거합니다.
지역별 시장 점유율
북미, 시장 점유율 약 38.4% 차지
북미는 새로운 치료법, 신제품 출시, FDA 승인, 선진 의료 인프라, 견고한 의료비 지출 등 여러 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.

예를 들어, 2023년 2월 우드랜드 하이츠 메디컬 센터는 러프킨/나코도치스 지역에서 최초로 폐색전증 및 심부정맥혈전증에 대한 새로운 치료법을 도입했습니다. 이는 FDA 승인을 받고 해당 치료를 위해 특별히 제작된 최초의 기계적 혈전 제거 장치입니다.
심부정맥혈전증(DVT)은 일반적으로 다리에 혈전이 형성될 때 발생하며, 폐색전증(PE)은 혈전의 일부가 떨어져 나와 혈류를 따라 이동하여 폐로 가는 혈류를 차단할 때 발생합니다. 혈류 차단으로 인해 우심실이 혈전을 통과하여 혈액을 밀어낼 수 없게 되어 우심장에 부담이 가중됩니다. 심한 경우 우심부전이 발생하여 사망에 이를 수 있습니다.

또한, 혁신적인 치료법에 주력하는 글로벌 헬스케어 기업인 페넘브라(Penumbra, Inc.)는 2023년 1월 미국 식품의약국(FDA)의 승인을 받아 시장에서 가장 진보되고 강력한 기계식 혈전 제거 시스템인 라이트닝 플래시(Lightning Flash)를 출시했다고 발표했습니다. 라이트닝 플래시는 페넘브라의 혁신적인 라이트닝 인텔리전트 흡인(Lightning Intelligent Aspiration) 기술을 특징으로 하며, 이제 이중 혈전 감지 알고리즘을 탑재했습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 애보트 연구소(Abbott Laboratories), 에드워드 라이프사이언스(Edward Lifesciences Corporation), 메드트로닉(Medtronic Inc.), 텔레플렉스 메디컬(Teleflex Medical), 보스턴 사이언티픽(Boston Scientific Corporation), 바이오트로닉(Biotronik), 메리트(Merit), B. 브라운(B. Braun SE), 테루모(Terumo Corporation), 페넘브라(Penumbra Inc.) 등이 있습니다.
코로나19 영향 분석
팬데믹 초기에는 의료 자원이 코로나19 환자 치료에 집중되면서 많은 기존 말초혈관 혈전 관리 치료가 연기되거나 취소되었습니다. 그 결과, 시술 건수와 관련 의료 기기 및 의약품 시장이 단기적으로 감소했습니다.

또한, 코로나19 환자에게서 나타나는 원인 불명의 혈전은 SARS-CoV-2 스파이크 단백질이 혈관 내피 세포의 ACE2 수용체와 결합하는 것과 관련이 있을 수 있습니다. 이러한 상호작용은 혈관 수축과 내인성 응고 경로의 활성화를 유발하여 혈전 형성을 초래합니다. SARS-CoV-2의 병원성과 RAS에서 ACE2의 역할 또한 고려되고 있습니다.
주요 개발 사항
 2023년 3월, SMT는 인도 내 일부 지역에서 페넘브라(Penumbra)의 말초 및 관상동맥 혈관 혈전 제거 기술의 독점 유통업체로 선정되었다고 발표했습니다. 본 계약 조건에 따라 SMT는 의료 서비스 제공업체에 페넘브라의 최신 인디고 시스템 포트폴리오를 제공할 예정입니다. 여기에는 최근 인도 CDSCO(중앙 의약품 표준 관리 기구) 승인을 받은 CAT™ RX와 규제 승인을 받는 대로 관상동맥 혈전증, 정맥 혈전증, 동맥 혈전증 및 폐색전증과 같은 질환을 치료하는 데 사용될 라이트닝 기술이 포함됩니다.
 혁신적인 치료법에 주력하는 글로벌 헬스케어 기업인 페넘브라는 2021년 3월, 인디고 시스템 라이트닝 7의 미국 시장 출시를 발표했습니다. 라이트닝 7은 기계적 혈전 제거를 위한 지능형 흡인 기능을 갖춘 인디고 흡인 시스템의 제품군을 확장한 것으로, 단일 세션으로 동맥 혈전을 제거하도록 설계되었습니다.

보고서 구매 이유:

• 기기 유형, 적응증, 최종 사용자 및 지역별 전 세계 말초 혈관 혈전 관리 시술 시장 세분화를 시각화하고 주요 상업 자산 및 업체들을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 글로벌 말초혈관 혈전 관리 시술 시장의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 말초혈관 혈전 관리 시술 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Peripheral Vascular Clot Management Interventions Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
Early detection and treatment of blood clots can significantly reduce the death rate due to stroke and vascular diseases. Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Platelets (a type of blood cell) and proteins in your plasma (the liquid part of the blood) work together to stop the bleeding by forming a clot over the injury.
Furthermore, the global peripheral vascular clot management interventions market is driven by various factors like the rising global incidence of cardiovascular diseases, technological advancements in clot management devices, continuous development of such cutting-edge technologies and others that will help this market to grow during the forecast period having significant key players like Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc, Teleflex Medical and others.
Dynamics
Rising Prevalence of Vascular Diseases
The rise in the prevalence of vascular diseases is one of the key factors that helps the market to grow during the forecast period. The prevalence of conditions like peripheral artery disease (PAD) and deep vein thrombosis (DVT) has been on the rise, primarily due to lifestyle factors like smoking, obesity, and sedentary behaviour. This drives the need for clot management interventions.
For instance, according to the Centers for Disease Control and Prevention updated factsheet The precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States.
Increase in the Incidence of Geriatric Population
Older individuals often face a higher risk of developing blood clots due to age-related factors such as reduced mobility, chronic health conditions (e.g., hypertension, diabetes, heart disease), and medications they may be taking. For instance, The World Health Organization (WHO) estimates that by 2050, there will be 2.1 billion people worldwide who are 60 years of age or older, up from 1 billion in 2020.
In addition, several sources and research show that the population aged 60 years or more is the foremost independent risk factor for deep vein thrombosis (when a blood clot forms in one or more of the deep veins in the body). Thus, the increasing geriatric population coupled with the burden of thrombosis among them is expected to create demand for clot management devices, thereby driving the market growth over the analysis period.

High Cost of Devices
Peripheral vascular clot management intervention devices can be costly, which can be a barrier to access for some patients. The high cost of these devices is due to the complexity of the procedures and the advanced technology used in the devices.
For instance, endovascular aneurysm repair stent grafts costs are very high which can be a restraint factor that hamper the market growth during the forecast period. The median cost of hospitalization for aneurysm-related subsequent intervention was $22,023 (IQR, $13,177-$47,752), compared with a median non-aneurysm-related subsequent intervention cost of $19,007 (IQR, $8708-$33,301).
For more details on this report Request for sample
Segment Analysis
The global peripheral vascular clot management interventions market is segmented based on device type, indication, end-user and region.
The Catheters Segment From the Device Type Segment Accounted For Approximately 41.7% of Peripheral Vascular Clot Management Interventions Share
The catheters segment from the device type segment accounted for 41.7% and it is expected to be dominated during the forecast period. The catheters are used to send clot-dissolving medicine to the DVT. This can help break up the clot or else the healthcare provider might use small tools to help break up the clot.
Catheter-directed thrombolysis treats vascular blockages and improves blood flow by dissolving abnormal blood clots. A blood clot, or thrombus, can block off blood supply to certain parts of the body and cause serious damage. Catheter-directed thrombolysis uses X-ray imaging and a catheter to guide special medication or a medical device to the site of a blood clot to dissolve the blockage.
For instance, in September 2021 Boston Scientific Corporation stated an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like novel treatment, new device launches, FDA Clearance, advanced healthcare infrastructure, Robust Healthcare Spending and other factors that help this region to grow during the forecast period.
For instance, in February 2023 Woodland Heights Medical Center is the first in the Lufkin/Nacogdoches area to utilize a new treatment for pulmonary embolism and deep vein thrombosis. It is the first mechanical thrombectomy device FDA indicated and purpose-built for this treatment.
Deep vein thrombosis (DVT) typically occurs when a blood clot forms in the legs and pulmonary embolism (PE) occurs when a part of the clot breaks off, travels through the bloodstream and causes a blockage of blood flow to the lungs. The blockage of blood flow results in right heart strain as the right ventricle is unable to push blood past the clot. In severe cases, right heart failure may occur leading to a fatal event.
Moreover, in January 2023 Penumbra, Inc. a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's novel Lightning Intelligent Aspiration technology, now with dual clot detection algorithms.
Competitive Landscape
The major global players in the market include Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc., Teleflex Medical, Boston Scientific Corporation., Biotronik, Merit, B. Braun SE, Terumo Corporation, Penumbra Inc and among others.
COVID-19 Impact Analysis
During the early phases of the pandemic, many conventional peripheral vascular clot management treatments were postponed or cancelled as healthcare resources were redirected to treat COVID-19 patients. As a result, procedure numbers and the market for associated medical devices and medications declined in the short term.
Also, the mysterious clots in COVID-19 patients may be due to the binding of the SARS-CoV-2 spike protein with the ACE2 receptor in blood vessel endothelial cells. This interaction has caused vasoconstriction and activation of the intrinsic coagulation pathway, leading to the formation of blood clots. The pathogenesis of SARS-CoV-2 and the role of ACE2 in RAS are also considered.
Key Developments
 In March 2023 SMT stated that it has been selected as the exclusive distributor of Penumbra’s peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Under the terms of the agreement, SMT will provide healthcare providers with Penumbra’s latest Indigo System portfolio, including CATTM RX, which recently received India CDSCO (Central Drug Standard Control Organization) approval, and Lightning technologies, upon regulatory approval, to address conditions such as coronary thrombosis, venous thrombosis, arterial thrombosis and pulmonary embolism.
 In March 2021 Penumbra, Inc., a global healthcare company focused on innovative therapies, stated U.S. commercial availability of the Indigo System Lightning 7. Lightning 7 expands Penumbra’s offering of the Indigo Aspiration System with Intelligent Aspiration for mechanical thrombectomy and is designed for single-session arterial thrombus removal.
Why Purchase the Report?
• To visualize the global peripheral vascular clot management interventions market segmentation based on device type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global peripheral vascular clot management interventions market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global peripheral vascular clot management interventions market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Device Type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Vascular Diseases
4.1.1.2. Increase in the Incidence of Geriatric Population
4.1.2. Restraints
4.1.2.1. High Cost of Devices
4.1.3. Opportunity
4.1.3.1. Rise in the Product Launches in Emerging Markets
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Device Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
7.1.2. Market Attractiveness Index, By Device Type
7.2. Catheters*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Endovascular Aneurysm Repair Stent Grafts
7.4. Inferior Vena Cava Filters
7.5. Plaque Modification Devices
7.6. Hemodynamic Flow Alteration Device
7.7. Other Peripheral Vascular Devices
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Deep Vein Thrombosis (DVT) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pulmonary Artery Embolism
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Specialty Clinics
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Abbott Laboratories*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Edward Lifesciences Corporation.
12.3. Medtronic Inc.
12.4. Teleflex Medical.
12.5. Boston Scientific Corporation.
12.6. Biotronik
12.7. Merit
12.8. B. Braun SE
12.9. Terumo Corporation
12.10. Penumbra Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Abbott Laboratories, 4. Key Developments, Edward Lifesciences Corporation., Medtronic Inc., Teleflex Medical., Boston Scientific Corporation., Biotronik, Merit, B. Braun SE, Terumo Corporation, Penumbra Inc

표 목록 (Tables)

List of Tables Table 1 Global Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Peripheral Vascular Clot Management Interventions Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 7 Global Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 9 Global Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 11 Global Peripheral Vascular Clot Management Interventions Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Peripheral Vascular Clot Management Interventions Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 14 North America Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 15 North America Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 16 North America Peripheral Vascular Clot Management Interventions Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 18 South America Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 19 South America Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 20 South America Peripheral Vascular Clot Management Interventions Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 22 Europe Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 23 Europe Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 24 Europe Peripheral Vascular Clot Management Interventions Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Value, By Device Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Value, By Indication, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Value, By End-User, 2021-2030 (US$ Billion)

Table 32 Abbott Laboratories.: Overview

Table 33 Abbott Laboratories.: Product Portfolio

Table 34 Abbott Laboratories.: Key Developments

Table 35 Edward Lifesciences Corporation.: Overview

Table 36 Edward Lifesciences Corporation.: Product Portfolio

Table 37 Edward Lifesciences Corporation.: Key Developments

Table 38 Medtronic Inc.: Overview

Table 39 Medtronic Inc.: Product Portfolio

Table 40 Medtronic Inc.: Key Developments

Table 41 Teleflex Medical..: Overview

Table 42 Teleflex Medical..: Product Portfolio

Table 43 Teleflex Medical..: Key Developments

Table 44 Boston Scientific Corporation.: Overview

Table 45 Boston Scientific Corporation.: Product Portfolio

Table 46 Boston Scientific Corporation.: Key Developments

Table 47 Biotronik: Overview

Table 48 Biotronik: Product Portfolio

Table 49 Biotronik: Key Developments

Table 50 Merit: Overview

Table 51 Merit: Product Portfolio

Table 52 Merit: Key Developments

Table 53 B. Braun SE: Overview

Table 54 B. Braun SE: Product Portfolio

Table 55 B. Braun SE: Key Developments

Table 56 Terumo Corporation: Overview

Table 57 Terumo Corporation: Product Portfolio

Table 58 Terumo Corporation: Key Developments

Table 59 Penumbra Inc: Overview

Table 60 Penumbra Inc: Product Portfolio

Table 61 Penumbra Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 3 Global Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 4 Global Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 5 Global Peripheral Vascular Clot Management Interventions Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Peripheral Vascular Clot Management Interventions Market Y-o-Y Growth, By Device Type, 2022-2030 (%)

Figure 7 Catheters Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 8 Endovascular Aneurysm Repair Stent Grafts Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 9 Inferior Vena Cava Filters Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 10 Plaque Modification Devices Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 11 Hemodynamic Flow Alteration Device Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 12 Other Peripheral Vascular Devices Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Peripheral Vascular Clot Management Interventions Market Y-o-Y Growth, By Indication, 2022-2030 (%)

Figure 14 Deep Vein Thrombosis (DVT) Indication in Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 15 Pulmonary Artery Embolism Indication in Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 16 Global Peripheral Vascular Clot Management Interventions Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospitals End-User in Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 18 Ambulatory Surgical Centers End-User in Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 19 Speciality Clinics End-User in Global Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 20 Global Peripheral Vascular Clot Management Interventions Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 22 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 23 Europe Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 24 South America Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 25 Middle East and Africa Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 26 North America Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 27 North America Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 28 North America Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 29 North America Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 30 North America Peripheral Vascular Clot Management Interventions Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 32 South America Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 33 South America Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 34 South America Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 35 South America Peripheral Vascular Clot Management Interventions Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 37 Europe Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 38 Europe Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 39 Europe Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 40 Europe Peripheral Vascular Clot Management Interventions Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 42 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 44 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 45 Asia-Pacific Peripheral Vascular Clot Management Interventions Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Value, 2021-2030 (US$ Billion)

Figure 47 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Share, By Device Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Share, By Indication, 2022 & 2030 (%)

Figure 49 Middle East & Africa Peripheral Vascular Clot Management Interventions Market Share, By End-User, 2022 & 2030 (%)

Figure 50 Abbott Laboratories.: Financials

Figure 51 Edward Lifesciences Corporation.: Financials

Figure 52 Medtronic Inc.: Financials

Figure 53 Teleflex Medical..: Financials

Figure 54 Boston Scientific Corporation.: Financials

Figure 55 Biotronik: Financials

Figure 56 Merit: Financials

Figure 57 B. Braun SE: Financials

Figure 58 Terumo Corporation: Financials

Figure 59 Penumbra Inc: Financials

글로벌 말초혈관 혈전 관리 시술 시장 – 2023-2030

Global Peripheral Vascular Clot Management Interventions Market -2023-2030